ERP29 and breast carcinoma: In particular, they observed that ERp29 induced the overexpression of Hsp27 by downregulating the expression of eukaryotic translational initiation factor 2α (eIF2α), while the knockdown of Hsp27 in MDA-MB-231 breast cancer cells overexpressing ERp29, attenuated the doxorubicin resistance [87].